Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures

Acta Orthopaedica

Volumn 84, Issue 5, 2013, Pages 495-501

  Berthold, Elisabet ^a   Geborek, Pierre ^a   Gülfe, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CLINDAMYCIN; CLOXACILLIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTHRODESIS; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTIVE SURGERY; FEMALE; FOOT SURGERY; HAND SURGERY; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORTHOPEDIC IMPLANT; ORTHOPEDIC SURGERY; OSTEOSYNTHESIS; PERIOPERATIVE PERIOD; PREDICTIVE VALUE; PSORIATIC ARTHRITIS; PUBLIC HEALTH SERVICE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SURGICAL INFECTION; SURGICAL TECHNIQUE; SYNOVECTOMY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HAND; HUMANS; INCIDENCE; MALE; METHOTREXATE; MIDDLE AGED; SURGICAL PROCEDURES, ELECTIVE; SURGICAL WOUND INFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887471472     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2013.842431     Document Type: Article

References (36)

1. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol (5 Suppl 39) 2005; 23: S100-8. (Pubitemid 46657517)
2. Askling J, Fored M C, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66 (10): 1339-44. (Pubitemid 47492478)
3. Bibbo C, Goldberg J W. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy Foot Ankle Int 2004; 25 (5): 331-5. (Pubitemid 39096154)
4. Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions fewer answers and some opinions J, Rheumatol 2007; 34 (4): 653-5. (Pubitemid 46641364)
5. Bongartz T, Sutton A J, Sweeting M J, Buchan I, Matteson E L, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trial. JAMA 2006; 295 (19): 2275-85. (Pubitemid 43736578)
6. den Broeder A, Creemers M C W, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study J Rheumatol 2007,34 , 4, 689-95. (Pubitemid 46641372)
7. Ding T, Ledingham J, Luqmani R et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies Rheumatology (Oxford) 2010; 49 (11): 2217-9.
8. Dixon W G, Watson K, Lunt M et al. Rates of serious infection including site-specific and bacterial intracellular infection in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis Rheum 2006; 54 (8): 2368-76. (Pubitemid 44204996)
9. Doran M F, Crowson C S, Pond G R, OFallon W M, Gabriel S E. Predictors of infection in rheumatoid arthritis Arthritis Rheum 2002; 46 (9): 2294-300.
10. Ekdahl C, Eberhardt K, Andersson S I, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a, Swedish version of the Stanford Health Assessment Questionnaire Scand J, Rheumatol 1988; 17 (4): 263-71.
11. Feldmann M, Maini R N. Discovery of TNF-alpha as a, therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002; 69 (1): 12-8. (Pubitemid 34123340)
12. Galloway J B, Hyrich K L, Mercer L K et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis 2011; 70 (10): 1810-4.
13. Giles J T, Bartlett S J, Gelber A C et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006; 55 (2): 333-7.
14. Gilson M, Gossec L, Mariette X et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor alpha-blockers: a casecontrol study. Arthritis Res Ther 2010; 12 (4): R145.
15. Grennan D M, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60 (3): 214-7. (Pubitemid 32260601)
16. Horan T C, Gaynes R P, Martone W J, Jarvis W R, Emori T G. CDC definitions of nosocomial surgical site infections 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13 (10): 606-8.
17. Hämäläinen M, Raunio P, Von Essen R, Postoperative wound infection in rheumatoid arthritis surgery. Clin Rheumatol 1984, 3, 329-35.
18. Kawakami K, Katsunori I, Kawamura K et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-{alpha} blockers: perioperative interruption of tumour necrosis factor-{alpha} blockers decreases complications Rheumatology (Oxford) 2010; 49 (2): 341-7.
19. Leombruno J P, Einarson T R, Keystone E C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68 (7): 1136-45.
20. Liang K Y, Zeger S L. Longitudinal data analysis using generalized linear models. Kung-Yee Liang; Scott L. Zeger. Biometrika 1986; 73 (1)
21. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52 (11): 3403-12. (Pubitemid 41612206)
22. Momohara S, Kawakami K, Iwamoto T et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21 (5): 469-75.
23. Pappas D A, Giles J T. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections Curr Opin Rheumatol 2008; 20 (4): 450-6.
24. Pham T, Claudepierre P, Deprez X et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI) section of the French Society of Rheumatology (Societe Francaise de Rhumatologie SFR) Joint Bone Spine (Suppl 1) 2005; 72: S1-58.
25. Poss R, Thornhill T S, Ewald F C, Thomas W H, Batte N J, Sledge C B. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop 1984; (182): 117-26. (Pubitemid 14182851)
26. Prentice R L. Correlated binary regression with cCovariates specific to each binary observation. Biometrics 1988; 44 (4): 1033-48. (Pubitemid 19026036)
27. Ruyssen-Witrand A, Gossec L, Salliot C et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007; 25 (3): 430-6. (Pubitemid 47091020)
28. Saag K G, Teng G G, Patkar N M et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59 (6): 762-84. (Pubitemid 351847559)
29. Salliot C, Gossec L, Ruyssen-Witrand A et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007; 46 (2): 327-34. (Pubitemid 46189796)
30. SAS Institute Inc. Generalized Estimating Equation (GEE) to handle correlated data. PROC GENMOD in the SAS System 9.3. (Cary NC USA) 2011.
31. Scanzello C R, Figgie M P, Nestor B J, Goodman S M. Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J 2006; 2 (2): 141-7. (Pubitemid 44328110)
32. Schrama J C, Espehaug B, Hallan G et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective population-based study on 108 786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res (Hoboken) 2010; 62 (4): 473-9.
33. Soderlin M K, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in Southern Sweden. Ann Rheum Dis 2008; 67: 37-42.
34. Suzuki M, Nishida K, Soen S et al. Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. J Orthop Sci 2011; 16 (6): 778-84.
35. Talwalkar S C, Grennan D M, Gray J, Johnson P, Hayton M J. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005; 64 (4): 650-1. (Pubitemid 40469105)
36. Wendling D, Balblanc J-C Brousse A et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 2005; 64 (9): 1378-9. (Pubitemid 41206266)